Hemophilia B, also known as Christmas disease, is a bleeding disorder. Its characteristic feature is a deficiency of clotting factor IX. This is a protein present in the blood that helps with ...

A new review article illuminates why physicians should keep coagulation disorders in mind when evaluating patients with heavy abnormal uterine bleeding. Physicians treating patients with heavy ...

The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates. A phase 3 trial of valoctocogene roxaparvovec, ...

Hemophilia A and B are similar conditions that affect the blood’s ability to clot. They typically occur due to gene variations that affect different blood clotting factors. Hemophilia is a group of ...

Hemophilia C is a rare, inherited blood disorder due to a deficiency of blood clotting protein Factor XI. It’s less severe than hemophilia A and B and is inherited differently. Still, it can cause ...

The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to ...

A recent study provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that saliva contains ...

In clinical laboratory settings, coagulation factor tests are routinely conducted to identify inherited or acquired deficiencies in patients suspected of an ongoing bleeding risk. These tests ...

NovoSeven RT is a prescription drug used to treat certain blood clotting disorders, including hemophilia. The drug is given as an intravenous (IV) infusion, which is an injection into a vein over a ...

Mixing studies have traditionally been used to differentiate factor deficiencies vs. inhibitors. To kick-start, we will provide a historical overview of how mixing studies were instrumental for the ...